You are receiving this message as a subscriber to the FDA HIV/AIDS electronic list serve. The purpose of the list serve is to relay important information about HIV/AIDS-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.
Please do not reply to this message.
On July 25, 2013, at 1:30PM (ET), FDA will present a webinar on a new draft guidance entitled "Draft Guidance for Industry on Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment"
This webinar,intended to encourage the submission of questions or comments while the guidance is still in draft form, will provide an opportunity to learn about the guidance from individuals involved in its preparation.
Questions may be submitted online during the webinar and will be addressed as time permits. All comments should also be submitted to docket so that they can be formally processed by FDA.
DRAFT Guidance
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM355128.pdf
Federal Register Notice
http://www.gpo.gov/fdsys/pkg/FR-2013-06-05/pdf/2013-13288.pdf
The Comment Period Will Close on 08/09/2013.
Please plan to join. Your comments are important.
Richard Klein
Office of Health and Constituent Affairs
Food and Drug Administration
Kimberly Struble
Division of Antiviral Products
Food and Drug Administration
Steve Morin
Office of Health and Constituent Affairs
Food and Drug Administration
| This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
